← Back to headlines
Gilead Sciences to Acquire Tubulis for $5B to Boost Oncology Pipeline
Gilead Sciences (GILD) announced its intention to acquire Tubulis for $5 billion, a strategic move to strengthen its oncology drug pipeline.
10 Apr, 04:43 — 10 Apr, 04:43
Sources
Showing 1 of 1 sources
